- $93.09m
- $92.54m
- $27.64m
Brief: ImmuCell Q3 Loss Per Share $0.07
Brief: ImmuCell Enters Into Lease Agreement For Facility To Expand First Defense Production Capacity
Brief: ImmuCell Announces An Agreement Covering The Formulation And Aseptic Filling Of Syringes For Re-Tain
Brief: ImmuCell Receives FDA Response To First CMC Submission For Re-Tain
Brief: ImmuCell Says Q2 Loss Per Share of $0.09
Brief: ImmuCell Posts Q1 Earnings Per Share Of $0.03
Immucell: Hits 16-month low as $9 mln stock deal prices
Brief: Immucell Corp Announces Pricing Of $9.0 Million Public Offering Of Common Stock
Brief: Immucell Corp Announces Commencement Of Public Offering Of Common Stock
Brief: Immucell Announces Submission Of Manufacturing Technical Section For Purified Nisin Product
Brief: Immucell Reports Q4 Loss Per Share Of $0.19
Brief: ImmuCell Announces USDA Approval Of Dual-Force First Defense
Brief: Immucell Corp Files For Mixed Shelf Of Up To $20 Million
Brief: ImmuCell Q3 Loss Per Share $0.05
Brief: ImmuCell Announces Issuance Of Human Food Safety Technical Section Complete Letter
Brief: ImmuCell Q2 Loss Per Share $0.15
Brief: Immucell Sees Q2 Product Sales $3 Mln Versus $1.8 Mln
Brief: ImmuCell Q1 Loss Per Share $0.04
Brief: ImmuCell Announces Q4 Loss Per Share $0.04